Tirzepatide reduces new aortic stenosis risk by 10% and all-cause mortality by 12% in obese patients
Background
Obesity is a significant risk factor for developing degenerative aortic stenosis (AS), a progressive heart valve disease. Despite its prevalence, no pharmacologic therapy has been established to prevent AS onset. Tirzepatide, a dual GIP/GLP-1 receptor agonist, offers superior metabolic and anti-inflammatory benefits over conventional GLP-1 RAs. This study investigates whether these broader benefits translate into a reduced risk of incident AS, addressing a critical gap in cardiovascular prevention strategies for obese individuals.
Study Design
This retrospective cohort study utilized the TriNetX global federated database, identifying 584,236 adults aged ≥18 years with obesity who initiated tirzepatide or GLP-1 RAs between 2022 and 2025. An active-comparator, new-user design with 1:1 propensity score matching (PSM) was applied to balance baseline characteristics. The primary endpoint was a composite of newly diagnosed AS or aortic valve replacement (AVR). Secondary outcomes included individual AS, AVR, and all-cause mortality. Cox proportional hazards models estimated hazard ratios (HRs) with 95% confidence intervals (CIs).
Results
After PSM, 584,236 patients were included in the analysis. During follow-up, tirzepatide users demonstrated a significantly lower risk of the composite endpoint of AS or AVR compared with GLP-1 RA users. The incidence was 0.2% for tirzepatide vs. 0.6% for GLP-1 RA users, resulting in an HR 0.90 (95% CI 0.81-0.98; P=0.022).
Key Findings
- Tirzepatide users had a 10% lower risk of newly diagnosed AS or AVR compared to GLP-1 RA users (HR 0.90, P=0.022).
- Newly diagnosed AS risk was 10% lower with tirzepatide (HR 0.90, P=0.025).
- All-cause mortality was 12% lower with tirzepatide (HR 0.88, P=0.001).
- No association was observed for the negative-control outcome of skin cancer.
- Protective associations were stronger in women and adults ≥65 years.
Why It Matters
Tirzepatide could emerge as the first pharmacologic therapy to prevent the onset of aortic stenosis in patients with obesity, significantly expanding its clinical utility beyond metabolic benefits. This finding suggests a novel cardioprotective role, potentially altering treatment paradigms for obese individuals at risk of AS. Clinicians might consider tirzepatide earlier for obese patients with cardiovascular risk factors, particularly women and those over 65 years, given the stronger protective associations observed in these subgroups. While specific dosing for AS prevention isn't outlined, the real-world data supports its use within existing metabolic protocols, offering an additional long-term benefit. This opens avenues for future randomized controlled trials to confirm causality and establish optimal preventative strategies.
tirzepatide
obesity
aortic-stenosis
cardiovascular
glp-1-agonist
gip-agonist